<DOC>
<DOCNO>EP-0612723</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Substituted benzoylguanidines, process for their preparation, their use as medicament, as inhibitor of the cellular Na+/H+ exchange or as diagnostic agent and medicament containing them
</INVENTION-TITLE>
<CLASSIFICATIONS>A61P900	C07C27922	C07D21700	A61P310	C07D21330	A61P912	C07D21718	A61K3144	C07D21550	C07D21356	C07C27918	C07D21500	A61P910	A61P3500	A61P1312	A61P104	C07D21724	A61P900	A61P3500	A61K31165	A61P4300	A61K3144	A61P4300	A61P1308	C07D21300	C07C27708	A61P906	C07C27700	A61P1100	A61K3147	A61P116	A61K31166	A61P1300	A61K3147	A61K31166	A61P300	A61P1100	A61K31472	A61K31165	C07D21514	C07C27900	A61P908	A61P902	A61P702	A61P100	A61K31472	A61P700	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61P	C07C	C07D	A61P	C07D	A61P	C07D	A61K	C07D	C07D	C07C	C07D	A61P	A61P	A61P	A61P	C07D	A61P	A61P	A61K	A61P	A61K	A61P	A61P	C07D	C07C	A61P	C07C	A61P	A61K	A61P	A61K	A61P	A61K	A61K	A61P	A61P	A61K	A61K	C07D	C07C	A61P	A61P	A61P	A61P	A61K	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61P9	C07C279	C07D217	A61P3	C07D213	A61P9	C07D217	A61K31	C07D215	C07D213	C07C279	C07D215	A61P9	A61P35	A61P13	A61P1	C07D217	A61P9	A61P35	A61K31	A61P43	A61K31	A61P43	A61P13	C07D213	C07C277	A61P9	C07C277	A61P11	A61K31	A61P1	A61K31	A61P13	A61K31	A61K31	A61P3	A61P11	A61K31	A61K31	C07D215	C07C279	A61P9	A61P9	A61P7	A61P1	A61K31	A61P7	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
There are described benzoylguanidines of the formula I 
<
IMAGE
>
 where R(1) to R(3) are H, Hal, (cyclo)alkyl, N3, CN, or OH, alkyloxy, phenyl, phenoxy or benzoyl, and their pharmacologically acceptable salts, but with the exception of the compounds benzoylguanidine, 4-chlorobenzoylguanidine, 3,4-dichlorobenzoylguanidine and 3- or 4-methylbenzoylguanidine. They are obtained by reaction of a compound II 
<
IMAGE
>
 where L is a leaving group, with guanidine.t
 
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
HOECHST AG
</APPLICANT-NAME>
<APPLICANT-NAME>
HOECHST AKTIENGESELLSCHAFT
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
ALBUS UDO DR
</INVENTOR-NAME>
<INVENTOR-NAME>
KLEEMANN HEINZ-WERNER DR
</INVENTOR-NAME>
<INVENTOR-NAME>
LANG HANS-JOCHEN DR
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHOLZ WOLFGANG DR
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHWARK JAN-ROBERT DR
</INVENTOR-NAME>
<INVENTOR-NAME>
WEICHERT ANDREAS DR
</INVENTOR-NAME>
<INVENTOR-NAME>
ALBUS, UDO, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
KLEEMANN, HEINZ-WERNER, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
LANG, HANS-JOCHEN, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHOLZ, WOLFGANG, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHWARK, JAN-ROBERT, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
WEICHERT, ANDREAS, DR.
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
A benzoylguanidine of the formula I 

 
in which: 


R(1), R(2), R(3) are 
hydrogen, F, Cl, Br, I or (C
1
-C
12
)-alkyl, 
one of the substituents R(1), R(2) or R(3) is 
N
3
, CN, OH or (C
1
-C
10
)-alkyloxy, if at least one 
of the remaining substituents R(1), R(2) or R(3) 

is a sufficiently lipophilic alkyl radical having 
3 to 12 carbon atoms, 
 
or one of the substituents R(1), R(2) or R(3) is
 
   R(4) -C
n
H
2n
-O
m
- where 

m is zero or 1, 
n is zero, 1, 2 or 3, 
R(4) is C
p
F
2p+1
 
   where p is 1, 2 or 3 if n is zero or 

1, or 
R(4) is (C
3
-C
12
)-cycloalkyl or phenyl, 
phenyl being unsubstituted or 

substituted by a substituent  
 

selected from the group consisting 
of 


F, Cl, CF
3
, methyl, methoxy or 
NR(5)R(6), 
where R(5) and R(6) are 
hydrogen or (C
1
-C
4
)-alkyl, 
 
or one of the substituents R(1), R(2) or R(3) is 

-C≡CR(5), -C[R(6)] = CR(5),
 
   R(5) is phenyl
 
      which is unsubstituted or 

substituted by 1-3 substituents 
selected from the group 

consisting of F, Cl, CF
3
, 
methyl, methoxy, hydroxyl, 

amino, methylamino or dimethylamino, 

(C
1
-C
9
)-heteroaryl,
 
   which is unsubstituted or 

substituted as phenyl, 
(C
1
-C
6
)-alkyl,
 
   which is unsubstituted or 

substituted by 1-3 OH, or 
(C
3
-C
8
)-cycloalkyl, 
 
      R(6) is hydrogen or methyl,
 
and the pharmacologically acceptable salts thereof,
 
with the exception of the compounds benzoylguanidine, 

4-chlorobenzoylguanidine, 3,4-dichlorobenzoylguanidine 
and 3- or 4-methylbenzoylguanidine. 
A benzoylguanidine of the formula I as claimed in 
claim 1, in which: 


R(1), R(2), R(3) are
 
   hydrogen, F, Cl, Br or (C
1
-C
8
)-alkyl, 
one of the substituents R(1), R(2) or R(3) is
 
   OH or (C
1
-C
6
)-alkyloxy, if at least one of the  
 

remaining substituents R(1), R(2) or R(3) is a 
sufficiently lipophilic alkyl radical having 

3 to 6 carbon atoms, 
 
or one of the substituents R(1), R(2) or R(3) is
 
   R(4)-C
n
H
2n
-O
m
- where 

m is zero or 1, 
n is zero, 1, 2 or 3, 
R(4) is C
p
F
2p+1
 
   where p is 1 if n is zero or 1, or 
R(4) is (C
5
-C
7
)-cycloalkyl or phenyl, 
phenyl being unsubstituted or 

substituted by a substituent 
selected from the group consisting 

of
 
      F, Cl, CF
3
, methyl or methoxy, 
 
or one of the substituents R(1), R(2) or R(3) is
 
   -C≡CR(5),
 
      R(5) is phenyl or (C
1
-C
4
)-alkyl,
 
         which is unsubstituted or 

substituted by an OH,
 
and the pharmacologically acceptable salts thereof,
 
with the exception of the compounds benzoylguanidine, 

4-chlorobenzoylguanidine, 3,4-dichlorobenzoylguanidine 
and 3- or 4-methylbenzoylguanidine. 
A benzoylguanidine of the formula I as claimed in 
claim 1, selected from the group comprising 3-trifluoromethylbenzoylguanidine 

hydrochloride, 3,5-bis-trifluoromethylbenzoylguanidine 
hydrochloride, 

3-methyl-5-trifluoromethylbenzoylguanidine hydrochloride, 
4-fluoro-3-trifluoromethylbenzoylguanidine 

hydrochloride, 4-(4-fluorophenoxy)-3-trifluoromethylbenzoylguanidine 
hydrochloride, 5-fluoro-3-trifluoromethylbenzoylguanidine 

hydrochloride, 
3-chloro-4-isopropylbenzoylguanidine hydrochloride,  

 
4-tert-butyl-3-methoxybenzoylguanidine hydrochloride, 

3-tert-butyl-4-hydroxybenzoylguanidine 
hydrochloride and 3-tert-butyl-4-isopropylbenzoylguanidine 

hydrochloride. 
A process for the preparation of a compound I as 
claimed in claim 1, which comprises reacting a 

compound of the formula II 

 
in which R(1) to R(3) have the abovementioned 

meaning and L is a leaving group which can readily 
be substituted by a nucleophile, with guanidine. 
The use of a compound I as claimed in claim 1 for 
the preparation of a pharmaceutical for the treatment 

of arrhythmias. 
The use of a compound I as claimed in claim 1 for 
the preparation of a pharmaceutical for the treatment 

of acute or chronic, ischemia-triggered types 
of damage or diseases which are primarily or 

secondarily induced by ischemia. 
The use of a compound I as claimed in claim 1 for 
the preparation of a pharmaceutical for the treatment 

of conditions after organ transplants, and for 
protecting the organs of the donor and the acceptor 

before and during removal and transfer to the 
acceptor. 
The use of a compound I as claimed in claim 1 for 
the preparation of a pharmaceutical for protecting  

 
organs when they are stored outside live organisms. 
The use of a compound I as claimed in claim 1 for 
the preparation of a pharmaceutical for protective 

purposes when carrying out invasive angioplastic 
treatment. 
The use of a compound I as claimed in claim 1 for 
the preparation of a pharmaceutical for the treatment 

of apoplexy and of cerebral edema. 
The use of a compound I as claimed in claim 1 for 
the preparation of a pharmaceutical for the treatment 

of shock conditions. 
The use of a compound I as claimed in claim 1 for 
the preparation of a pharmaceutical for the treatment 

of atherogenesis and atherosclerosis. 
The use of a compound I as claimed in claim 1 for 
the preparation of a pharmaceutical for the treatment 

of late complications in diabetes. 
The use of a compound I as claimed in claim 1 for 
the preparation of a pharmaceutical for the treatment 

of cancer. 
The use of a compound I as claimed in claim 1 for 
the preparation of a pharmaceutical for the treatment 

of fibrotic diseases. 
The use of a compound I as claimed in claim 1 for 
the preparation of a pharmaceutical for the treatment 

of organ hypertrophias and hyperplasias. 
The use of a compound I as claimed in claim 1 as 
scientific tools and diagnostics. 
The use of a compound I as claimed in claim 1 for  
 

the preparation of a pharmaceutical for preventing 
the genesis of hypertension. 
The use of a compound I as claimed in claim 1 for 
the preparation of a pharmaceutical for the treatment 

of disorders triggered by proliferative processes. 
The use of a compound I as claimed in claim 1 for 
the preparation of a pharmaceutical for the treatment 

of gastrointestinal disorders and disorders of 
the esophagus caused by hypersecretion of gastric 

acid. 
Medicament which comprises an effective amount of a 
compound I as claimed in claim 1. 
</CLAIMS>
</TEXT>
</DOC>
